Drugs / E004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01460511 | Oct 2011 → Mar 2012 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-11-08 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST amphastar.com ↗ |
| 2016-12-27 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist amphastar.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-11-08 | Amphastar Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST amphastar.com ↗ |
| 2016-12-27 | Amphastar Pharmaceuticals, Inc. | Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist amphastar.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01460511 ↗ |
| Known as | Epinephrine Inhalation Aerosol | “E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID” NCT01460511 ↗ |
| Route | Inhaled | “E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID” NCT01460511 ↗ |